Biologics are a highly effective therapeutic option with broad applicability across many indications. However, the traditional fed-batch manufacturing presents significant challenges, especially when upscaling from clinical to commercial supply. With a modular continuous manufacturing setup, the J.POD® technology allows for highly intensified cGMP manufacturing of biologics at flexibly scalable quantities, thus reducing both scale-up risks and manufacturing costs significantly. Evotec Biologics’ second J.POD® facility marks an important milestone on their path to making biologics globally available.
Phase 1 - Complete building and fit-out of 14,900 sq.m.; Phase 2 - Fit-out of remaining 700 sq.m.